DE69636902D1 - Lactacystin-analoge - Google Patents

Lactacystin-analoge

Info

Publication number
DE69636902D1
DE69636902D1 DE69636902T DE69636902T DE69636902D1 DE 69636902 D1 DE69636902 D1 DE 69636902D1 DE 69636902 T DE69636902 T DE 69636902T DE 69636902 T DE69636902 T DE 69636902T DE 69636902 D1 DE69636902 D1 DE 69636902D1
Authority
DE
Germany
Prior art keywords
lactacystin analog
lactacystin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636902T
Other languages
English (en)
Other versions
DE69636902T2 (de
Inventor
L Schreiber
F Standaert
Gabriel Fenteany
F Jamison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of DE69636902D1 publication Critical patent/DE69636902D1/de
Application granted granted Critical
Publication of DE69636902T2 publication Critical patent/DE69636902T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69636902T 1995-04-12 1996-04-12 Lactacystin-analoge Expired - Fee Related DE69636902T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/421,583 US6335358B1 (en) 1995-04-12 1995-04-12 Lactacystin analogs
US421583 1995-04-12
PCT/US1996/005072 WO1996032105A1 (en) 1995-04-12 1996-04-12 Lactacystin analogs

Publications (2)

Publication Number Publication Date
DE69636902D1 true DE69636902D1 (de) 2007-03-29
DE69636902T2 DE69636902T2 (de) 2007-11-22

Family

ID=23671162

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636902T Expired - Fee Related DE69636902T2 (de) 1995-04-12 1996-04-12 Lactacystin-analoge

Country Status (16)

Country Link
US (6) US6335358B1 (de)
EP (1) EP0820283B1 (de)
JP (1) JP4153032B2 (de)
KR (1) KR100493472B1 (de)
CN (1) CN1151787C (de)
AR (4) AR003415A1 (de)
AT (1) ATE353644T1 (de)
AU (1) AU705791C (de)
CA (1) CA2217817A1 (de)
DE (1) DE69636902T2 (de)
ES (1) ES2283001T3 (de)
HK (1) HK1008489A1 (de)
IL (1) IL117887A (de)
NZ (1) NZ306775A (de)
WO (1) WO1996032105A1 (de)
ZA (1) ZA962933B (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6838477B2 (en) 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
CA2281224A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
EP1017398A1 (de) * 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitoren, inhibitoren des ubiquitinweges oder verbindungen, die mit der durch den ubiquitinweg enstehenden nf-kb aktivierung interferieren zur behandlung von entzündlichen und autoimmunerkrankungen
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US5902818A (en) * 1997-12-09 1999-05-11 Auburn University Surface active N-halamine compounds
US6469177B1 (en) 1997-12-09 2002-10-22 Auburn University Surface active N-Halamine compounds
EP0943624A1 (de) * 1998-03-12 1999-09-22 Universiteit Utrecht Peptidische Inhibitoren der Verminderungsregulation des Wachstumhormone-Rezeptors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
CA2347275C (en) * 1998-10-20 2010-03-09 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
EP1053750A1 (de) * 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gebrauch von Proteasom-Inhibitor zur Induktion von programmiertem Zelltod (Apoptose)
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
AU2001281392A1 (en) * 2000-08-08 2002-02-18 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
DE10040742B4 (de) * 2000-08-17 2006-08-24 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Mittel zur Herz-Kreislauf-Protektion
PT1326632E (pt) * 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
WO2002052269A2 (en) * 2000-12-22 2002-07-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
WO2002080907A1 (en) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
MXPA03010632A (es) 2001-05-21 2004-03-09 Alcon Inc Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
EP1392355B1 (de) 2001-05-21 2007-02-14 Alcon, Inc. Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US20040014678A1 (en) * 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
US6548054B2 (en) 2001-09-06 2003-04-15 Auburn University Biocidal polystyrene hydantoin particles
US6969769B2 (en) * 2002-06-14 2005-11-29 Vanson Halosource, Inc. N-halamine siloxanes for use in biocidal coatings and materials
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7687072B2 (en) * 2002-10-31 2010-03-30 Auburn University Biocidal particles of methylated polystyrene
EP1581629B1 (de) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
JP4795931B2 (ja) * 2003-02-14 2011-10-19 インターメッド・ディスカバリー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換複素環
EP2441767B1 (de) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamide und Verwendungsverfahren dafür
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
US7371875B2 (en) 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
PT1745064E (pt) 2004-04-15 2011-03-23 Proteolix Inc Compostos para a inibição de uma enzima de proteassoma
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1812443A2 (de) * 2004-04-30 2007-08-01 Nereus Pharmaceuticals, Inc. [3,2,0]-heterocyclische verbindungen und verfahren zu ihrer verwendung
JP5108509B2 (ja) 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
EP1805208A2 (de) 2004-10-20 2007-07-11 Proteolix, Inc. Markierte verbindungen zur proteasomhemmung
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
CA2590334A1 (en) * 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
WO2006118973A2 (en) * 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US7465720B2 (en) * 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
US20080009545A1 (en) * 2006-02-21 2008-01-10 The Ohio State University Research Foundation Anticancer agents
KR20080109071A (ko) 2006-04-06 2008-12-16 니리어스 파마슈티컬즈, 인코퍼레이션 살리노스포라마이드 ａ 및 그의 유도체들의 전합성
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
DK2207791T4 (da) 2007-10-04 2019-10-07 Onyx Therapeutics Inc Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2262812A2 (de) 2008-03-07 2010-12-22 Nereus Pharmaceuticals, Inc. Totalsynthese von salinosporamid a und analoga davon
CN102089312A (zh) * 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
US20110111417A1 (en) 2008-05-14 2011-05-12 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
ES2617560T3 (es) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
EP2399129B1 (de) 2009-02-20 2015-11-25 Michael P. Lisanti Verfahren zur diagnose bzw. prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
EP2498793B1 (de) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib zur verwendung in der metastasensuppression
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
EP3187585A1 (de) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
RS55053B1 (sr) 2011-08-11 2016-12-30 Janssen Pharmaceutica Nv Prediktori za lečenje kancera
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
CA2853822A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP2776586B1 (de) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarker der reaktion auf proteasomenhemmer
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2013112881A1 (en) 2012-01-27 2013-08-01 Thomas Jefferson University Mct protein inhibitor-related prognostic and therapeutic methods
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2869820A4 (de) 2012-07-09 2016-02-17 Onyx Therapeutics Inc Prodrugs von peptidepoxidketonproteaseinhibitoren
JP6486826B2 (ja) 2012-10-01 2019-03-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
BR112015018095A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2973283T3 (es) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de receptores de NMDA espirolactámicos y usos de los mismos
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
AU2017306164B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3339291A1 (de) * 2016-12-22 2018-06-27 Vita Api Proteasomhemmende ss-lactam-prodrugs, die zur behandlung von krebs und neurodegenerativen erkrankungen nützlich sind
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60135469A (ja) * 1983-12-22 1985-07-18 Tokuyama Soda Co Ltd 接着性被膜形成材
DE3631414A1 (de) * 1986-09-16 1988-03-24 Basf Ag Verfahren zur herstellung von (alpha)-pyrrolidonen, deren verwendung und neue (alpha)-pyrrolidone
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5266588A (en) 1992-09-25 1993-11-30 Bristol-Myers Squibb Company Compound produced by a strain of microtetraspora having antibacterial and neuritogenic activity
US5453502A (en) * 1994-03-16 1995-09-26 Eli Lilly And Company 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes for preparation thereof
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs

Also Published As

Publication number Publication date
WO1996032105A1 (en) 1996-10-17
AU705791C (en) 2004-08-12
CN1151787C (zh) 2004-06-02
NZ306775A (en) 1999-10-28
CA2217817A1 (en) 1996-10-17
US6645999B1 (en) 2003-11-11
EP0820283B1 (de) 2007-02-14
US6458825B1 (en) 2002-10-01
AU705791B2 (en) 1999-06-03
US6335358B1 (en) 2002-01-01
HK1008489A1 (en) 1999-05-14
JPH11503732A (ja) 1999-03-30
AR014619A2 (es) 2001-03-28
US6147223A (en) 2000-11-14
KR100493472B1 (ko) 2007-04-04
JP4153032B2 (ja) 2008-09-17
AU5542396A (en) 1996-10-30
EP0820283A4 (de) 1998-07-08
ES2283001T3 (es) 2007-10-16
US5756764A (en) 1998-05-26
AR012172A2 (es) 2000-09-27
EP0820283A1 (de) 1998-01-28
US6214862B1 (en) 2001-04-10
CN1187769A (zh) 1998-07-15
IL117887A (en) 2006-08-20
AR003415A1 (es) 1998-08-05
ZA962933B (en) 1997-02-03
ATE353644T1 (de) 2007-03-15
IL117887A0 (en) 1996-08-04
KR19980703857A (ko) 1998-12-05
DE69636902T2 (de) 2007-11-22
AR011204A1 (es) 2000-08-02

Similar Documents

Publication Publication Date Title
DE69636902D1 (de) Lactacystin-analoge
DK0822982T3 (da) Cyclomaltodextringlucanotransferasevarianter
BR9609682A (pt) Foto-desinfetantes de baixa nuança
DE59602881D1 (de) Sollwertgeber
ID17719A (id) Asilasi 5-aminoisotiazol
ATA135896A (de) Skibob
NO981752L (no) Syklopeptidderivater
ATE198470T1 (de) Alkenyl-benzoylguanidine
PT839024E (pt) Formulacoes de monensina
ATE240972T1 (de) Cyclopeptolide
ATA119896A (de) Scheibenmähwerk
DE69621247D1 (de) Desensibilisierungszahnpasta
BR9501643A (pt) Helistato
KR970002869U (ko) 숫자 교습구
SE9501165D0 (sv) Hållaranordning
BR7500505U (pt) Amolador de facas
FI953908A0 (fi) Anordning til drag-, flygg- eller fallskaerm
FI2528U1 (fi) Pyykkinarukoukusto
FIU950203U0 (fi) Myllskydd + kruka
FIU950225U0 (fi) Foerandring mullskydd + kruka
BR7500991U (pt) Caríndio
BR7500192U (pt) Parasitofiltro
BR7500703U (pt) Rodopratic
BR7500825U (pt) Chutegol
BR7500838U (pt) Vassourágua

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee